Swiss National Bank Grows Stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Swiss National Bank grew its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 0.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,290,087 shares of the company’s stock after acquiring an additional 2,900 shares during the quarter. Swiss National Bank owned about 0.28% of GE HealthCare Technologies worth $100,859,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Ashton Thomas Securities LLC purchased a new position in shares of GE HealthCare Technologies in the 3rd quarter valued at $26,000. Darwin Wealth Management LLC purchased a new position in shares of GE HealthCare Technologies in the 3rd quarter valued at $31,000. Continuum Advisory LLC increased its holdings in shares of GE HealthCare Technologies by 101.8% in the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock valued at $31,000 after acquiring an additional 168 shares during the period. Bank of Jackson Hole Trust purchased a new position in shares of GE HealthCare Technologies in the 4th quarter valued at $32,000. Finally, OFI Invest Asset Management purchased a new position in shares of GE HealthCare Technologies in the 4th quarter valued at $34,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

GE HealthCare Technologies Stock Performance

Shares of GEHC opened at $81.97 on Friday. The stock has a 50-day moving average of $87.26 and a two-hundred day moving average of $86.10. GE HealthCare Technologies Inc. has a one year low of $74.51 and a one year high of $94.80. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.83 and a current ratio of 1.04. The stock has a market cap of $37.48 billion, a P/E ratio of 18.93, a P/E/G ratio of 3.19 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The company had revenue of $5.32 billion during the quarter, compared to analysts’ expectations of $5.33 billion. As a group, research analysts predict that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

Wall Street Analyst Weigh In

GEHC has been the topic of a number of analyst reports. Wells Fargo & Company lifted their price target on GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Citigroup raised their price objective on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. The Goldman Sachs Group raised GE HealthCare Technologies from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $85.00 to $100.00 in a research report on Tuesday. Finally, Jefferies Financial Group raised GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their price objective for the stock from $95.00 to $103.00 in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $98.75.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.